This week marked the official launch of Cmbio, a new services business that brings multiple microbiome and metabolomics companies under a single brand. 

The new business combines Clinical Microbiomics, a contract research organization that specializes in microbiome and metabolome analysis, CosmosID, a bioinformatics company focused on identifying microorganisms in metagenomic samples, and MS-Omics, a provider of metabolomics and data analysis services. Also included under the new brand are DNASense, a company that provides methods and bioinformatics for microbiomics analysis, and the Research Services unit of Microba, a precision microbiome science company. 

The combined company, which includes a team of over 100 experts in microbiome and metabolome science, will offer GxP lab services, advanced bioinformatics, and multiomics solutions that support research focused on improving human, animal, and planetary health. The company aims to provide a suite of services for the pharmaceutical, consumer, and biotechnology sectors as well as academic institutions that leverage bioinformatics, artificial intelligence, and integrative systems biology. 

Anders Grøn, who has been named CEO of Cmbio, said the new brand better reflects “the scope of our activities and our commitment to enable microbiome science in addressing critical global health and sustainability challenges.”

Some of the challenges they intend to address include issues with standardized sampling, data generation, and analysis. They will also provide access to GxP laboratory services that offer rapid turnaround times and comply with requisite regulations. The company also has its eyes set on playing a pivotal role in advancing digital biology through its integration of software, AI, and multiomics platforms. 

The company’s portfolio includes custom kits for microbiome sample collection, preservation, and transport; comprehensive microbial DNA sequencing services; and microbial gene expression profiling. Also available are targeted and untargeted metabolite panels for profiling microbial and host functional insights and health outcomes. Cmbio has laboratories in the United States and Denmark and a presence in the EU and APAC. 

Previous articleTrans-Atlantic Triumph: AI Drug Pioneers Recursion, Exscientia Combine
Next articleNovartis Buys Kate Therapeutics, Expanding in Neuro Gene Therapy